ウエストナイルウイルス治療法の世界市場予測・分析:用途別

Technavioが発行した調査報告書(IRTNTR32148)
◆英語タイトル:West Nile Virus Therapeutics Market by Application and Geography - Global Forecast & Analysis 2019-2023
◆商品コード:IRTNTR32148
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年10月
◆ページ数:152
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

Technavio社の本調査レポートでは、ウエストナイルウイルス治療法の世界市場について調べ、ウエストナイルウイルス治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、ウエストナイルウイルス治療法の市場規模をセグメンテーション別(用途別(神経侵襲性、非神経侵襲性)、)と地域別(グローバル)に分けて算出しました。Technavio社はウエストナイルウイルス治療法の世界市場規模が2019-2023期間中に年平均2%成長すると予測しています。
・サマリー
・レポートの範囲
・ウエストナイルウイルス治療法の市場状況
・ウエストナイルウイルス治療法の市場規模
・ウエストナイルウイルス治療法の市場予測
・ウエストナイルウイルス治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:用途別(神経侵襲性、非神経侵襲性)
・ウエストナイルウイルス治療法の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global West Nile Virus Therapeutics Market: About this market
Technavio’s West Nile virus therapeutics market analysis considers sales from both neuroinvasive and non-neuroinvasive applications. Our analysis also considers the sales of West Nile virus therapeutics in Asia, Europe, North America, and ROW. In 2018, the neuroinvasive segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as occurrence of different symptoms will play a significant role in the neuroinvasive segment to maintain its market position. Also, our global West Nile virus therapeutics market report looks at factors such as communicable nature of the disease, availability of over-the-counter (OTC) therapeutics, and availability of diagnostic tests. However, programs to control mosquito breeding, lack of approved therapies, and asymptomatic nature of the disease may hamper the growth of the West Nile virus therapeutics industry over the forecast period.

Global West Nile Virus Therapeutics Market: Overview
Availability of over-the-counter therapeutics
West Nile Virus infection does not have a specific drug or vaccine that is approved or ideal for patients. However, the CDC recommends the treatment of associated symptoms using OTC analgesics. OTC drugs such as aspirin and ibuprofen are the most commonly used drugs, which patients use to self-medicate and treat their illness at home. The purchase of these drugs does not require a prescription from a doctor and are of low cost. These benefits boost patient adherence and will lead to the expansion of the global West Nile virus therapeutics market at a CAGR of over 2% during the forecast period.

Rising awareness
In the absence of vaccines for the prevention of West Nile Virus infection, the only ways of reducing the health burden of the infection are by creating awareness among people about the risk factors and symptoms and educating people about the treatment measures. The increasing mosquito population poses the ever-growing threat of mosquito-borne illnesses worldwide, which is likely to encourage fresh players to enter the market to meet the rising demand for preventive and curative measures for these illnesses and is thus, anticipated to have a positive impact on market growth.
For the detailed list of factors that will drive the global West Nile virus therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global West Nile virus therapeutics market is fairly fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading West Nile virus therapeutics manufacturers, that include Aurobindo Pharma Ltd., Bayer AG, GlaxoSmithKline Plc, Granules India Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Also, the West Nile virus therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

Market segmentation by application

Comparison by application

Neuroinvasive – Market size and forecast 2018-2023

Non-neuroinvasive – Market size and forecast 2018-2023

Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Shifting epidemiology of Flaviviridae

Rising awareness

Growing risk of spreading infections via blood transfusions

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Aurobindo Pharma Ltd.

Bayer AG

GlaxoSmithKline Plc

Granules India Ltd.

Johnson & Johnson Services Inc.

Mylan NV

Novartis AG

Perrigo Co. Plc

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Vendors: Key offerings

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Application – Market share 2018-2023 (%)

Exhibit 19: Comparison by application

Exhibit 20: Neuroinvasive – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Neuroinvasive – Year-over-year growth 2019-2023 (%)

Exhibit 22: Non-neuroinvasive – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Non-neuroinvasive – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by application

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 36: Top 3 countries in Asia

Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in ROW

Exhibit 40: Key leading countries

Exhibit 41: Market opportunity

Exhibit 42: Impact of drivers and challenges

Exhibit 43: Vendor landscape

Exhibit 44: Landscape disruption

Exhibit 45: Vendors covered

Exhibit 46: Vendor classification

Exhibit 47: Market positioning of vendors

Exhibit 48: Aurobindo Pharma Ltd. – Vendor overview

Exhibit 49: Aurobindo Pharma Ltd. – Product segments

Exhibit 50: Aurobindo Pharma Ltd. – Organizational developments

Exhibit 51: Aurobindo Pharma Ltd. – Geographic focus

Exhibit 52: Aurobindo Pharma Ltd. – Key offerings

Exhibit 53: Aurobindo Pharma Ltd. – Key customers

Exhibit 54: Bayer AG – Vendor overview

Exhibit 55: Bayer AG – Business segments

Exhibit 56: Bayer AG – Organizational developments

Exhibit 57: Bayer AG – Geographic focus

Exhibit 58: Bayer AG – Segment focus

Exhibit 59: Bayer AG – Key offerings

Exhibit 60: Bayer AG – Key customers

Exhibit 61: GlaxoSmithKline Plc – Vendor overview

Exhibit 62: GlaxoSmithKline Plc – Business segments

Exhibit 63: GlaxoSmithKline Plc – Organizational developments

Exhibit 64: GlaxoSmithKline Plc – Geographic focus

Exhibit 65: GlaxoSmithKline Plc – Segment focus

Exhibit 66: GlaxoSmithKline Plc – Key offerings

Exhibit 67: GlaxoSmithKline Plc – Key customers

Exhibit 68: Granules India Ltd. – Vendor overview

Exhibit 69: Granules India Ltd. – Business segments

Exhibit 70: Granules India Ltd. – Organizational developments

Exhibit 71: Granules India Ltd. – Geographic focus

Exhibit 72: Granules India Ltd. – Segment focus

Exhibit 73: Granules India Ltd. – Key offerings

Exhibit 74: Granules India Ltd. – Key customers

Exhibit 75: Johnson & Johnson Services Inc. – Vendor overview

Exhibit 76: Johnson & Johnson Services Inc. – Business segments

Exhibit 77: Johnson & Johnson Services Inc. – Organizational developments

Exhibit 78: Johnson & Johnson Services Inc. – Geographic focus

Exhibit 79: Johnson & Johnson Services Inc. – Segment focus

Exhibit 80: Johnson & Johnson Services Inc. – Key offerings

Exhibit 81: Johnson & Johnson Services Inc. – Key customers

Exhibit 82: Mylan NV – Vendor overview

Exhibit 83: Mylan NV – Product segments

Exhibit 84: Mylan NV – Organizational developments

Exhibit 85: Mylan NV – Geographic focus

Exhibit 86: Mylan NV – Segment focus

Exhibit 87: Mylan NV – Key offerings

Exhibit 88: Mylan NV – Key customers

Exhibit 89: Novartis AG – Vendor overview

Exhibit 90: Novartis AG – Business segments

Exhibit 91: Novartis AG – Organizational developments

Exhibit 92: Novartis AG – Geographic focus

Exhibit 93: Novartis AG – Segment focus

Exhibit 94: Novartis AG – Key offerings

Exhibit 95: Novartis AG – Key customers

Exhibit 96: Perrigo Co. Plc – Vendor overview

Exhibit 97: Perrigo Co. Plc – Business segments

Exhibit 98: Perrigo Co. Plc – Organizational developments

Exhibit 99: Perrigo Co. Plc – Geographic focus

Exhibit 100: Perrigo Co. Plc – Segment focus

Exhibit 101: Perrigo Co. Plc – Key offerings

Exhibit 102: Perrigo Co. Plc – Key customers

Exhibit 103: Pfizer Inc. – Vendor overview

Exhibit 104: Pfizer Inc. – Business segments

Exhibit 105: Pfizer Inc. – Organizational developments

Exhibit 106: Pfizer Inc. – Geographic focus

Exhibit 107: Pfizer Inc. – Segment focus

Exhibit 108: Pfizer Inc. – Key offerings

Exhibit 109: Pfizer Inc. – Key customers

Exhibit 110: Teva Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 111: Teva Pharmaceutical Industries Ltd. – Business segments

Exhibit 112: Teva Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 113: Teva Pharmaceutical Industries Ltd. – Segment focus

Exhibit 114: Teva Pharmaceutical Industries Ltd. – Key offerings

Exhibit 115: Teva Pharmaceutical Industries Ltd. – Key customers

Exhibit 116: Validation techniques employed for market sizing

Exhibit 117: Definition of market positioning of vendors



【掲載企業】

Aurobindo Pharma Ltd.
Bayer AG
GlaxoSmithKline Plc
Granules India Ltd.
Johnson & Johnson Services Inc.
Mylan NV
Novartis AG
Perrigo Co. Plc
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ウエストナイルウイルス治療法の世界市場予測・分析:用途別(West Nile Virus Therapeutics Market by Application and Geography - Global Forecast & Analysis 2019-2023)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆